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Introduction
The tone of the 3-day meeting was set by Umberto
Veronesi (European Institute of Oncology, Milan, Italy) at
the opening session. The ongoing aim of primary therapy
in early breast cancer is moving from the concept of
‘maximum tolerated treatment’ to that of ‘minimum neces-
sary treatment’. Toward this goal, the St Gallen consensus
continues to strive to define a group of patients with
exceptionally good prognosis who require minimal primary
therapy, and much of the conference was concerned with
how to improve this definition, as well as how best to treat
the groups at higher risk for subsequent relapse. Through-
out the meeting a recurrent theme was the distinction
between prognostic information (which defines a level of
risk) and predictive information (which predicts response
to a particular therapy).
The St Gallen 2003 consensus statement is still being
written and will be published in the summer (in the Journal
of Clinical Oncology), and therefore we will not discuss its
likely content, but we review some of the key issues dis-
cussed at the plenary and poster sessions.
New prognostic and predictive markers in
early breast cancer
Daniel F Hayes (University of Michigan, Ann Arbor,
USA) introduced the concept of positive predictive
power as a means of assessing the validity of a predic-
tive marker. Martine Piccart (Jules Bordet Institute,
Brussels, Belgium) summarized promising new markers
that may have prognostic and predictive value in the
management of early breast cancer. These included
uPA/Pal-1, cyclin E and cDNA microarrays, but all of
these require further evaluation in prospective trials.
Stephen Braun (Universitätsklinikum, Innsbruck, Austria)
presented data suggesting that immunocytological
demonstration of bone marrow micrometastases has
independent prognostic value, and prospective evalua-
tion of this technique aimed at ascertaining its predic-
tive value is being planned.
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Abstract
The International St Gallen Breast Cancer Conference concentrates almost exclusively on adjuvant,
multimodal primary therapy for early breast cancer. Begun 25 years ago, this meeting was initially held
every 4 years, but therapeutic progress, new strategies and provocative trials data have accelerated to
the extent that conferences are now held biennially. The meeting this year was attended by almost
3000 delegates. Major topics included new prognostic and predictive markers in early breast cancer,
the best use of adjuvant chemotherapy and endocrine therapy, and innovations in local surgery and
radiation therapy.
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Adjuvant hormone therapy
The results of a large trial comparing the adjuvant use of
anastrazole and tamoxifen in combination have been dis-
cussed elsewhere [1], but many speakers speculated that
aromatase inhibitors are likely to play an increasing role in
the future adjuvant treatment of breast cancer. In particu-
lar, Kathleen Pritchard (Sunnybrook Regional Cancer
Centre, Toronto, Canada) discussed the need for further
studies examining their role in the treatment of endocrine
receptor positive, Her2 positive breast cancer. This was
supported by laboratory data from Kent Osborne (Baylor
College of Medicine, Houston, TX, USA). He presented
compelling laboratory evidence that forced high level
expression of Her2 in breast cancer cells stimulated the
agonist activity of tamoxifen in the nucleus in a manner
dependent upon activation of tyrosine kinase cascades.
Particularly fascinating was his observation that this
agonist activity of tamoxifen was reversed by the epider-
mal growth factor receptor tyrosine kinase inhibitor Iressa
(gefitinib, ZD1839, AstraZeneca, Alderley Park, Cheshire,
UK). These data offer significant new insight into cross-
talk between growth factor receptor pathways and steroid
receptors, and point toward possible strategies for thera-
peutic manipulation of tamoxifen resistance pathways.
Stefan Aebi (Inselspital, Institut für Medizinische Onkolo-
gie, Bern, Switzerland) and Pritchard both raised the issue
of optimization of adjuvant endocrine therapy and the role
of ovarian function suppression in young, premenopausal
women. Two new trials from the International Breast
Cancer Study Group (TEXT [Tamoxifen and Exemestane
Trial] and SOFT [Suppression of Ovarian Function Trial]
[2]) will address this issue.
How best to combine endocrine and
chemotherapy
Probably the most assertive new data presented at the
meeting came from Kathy Albain (Loyola University
Medical Centre, Chicago, IL, USA), who presented the
10-year update from the North American Intergroup trial
0100. This was a three-arm study comparing tamoxifen
alone with tamoxifen commenced at the same time as
CAF (cyclophosphamide, doxorubicin, 5-FU) chemother-
apy with tamoxifen commenced upon completion of the
same chemotherapy [3]. This confirmed previous overview
conclusions that tamoxifen confers a marked disadvantage
in disease-free survival (DFS) and overall survival (OS) if
administered during chemotherapy rather than on comple-
tion. However, Osborne warned that this effect might not
be the same for other forms of oestrogen manipulation
such as ovarian suppression or aromatase inhibition.
The issue of whether optimal endocrine therapy should
complement or substitute for chemotherapy still provoked
some debate, and this issue will be addressed in the
forthcoming International Breast Cancer Study Group
trial (PERCHE [Premenopausal Endocrine Responsive
Chemotherapy trial]) [2].
Advances in adjuvant chemotherapy
Piccart described mixed findings to date from the first
adjuvant trials using taxane-based chemotherapy regi-
mens. Although initial findings suggested statistically sig-
nificant differences in both DFS and OS with the addition
of a taxane, perhaps most notably in the US Intergroup
CALGB 9344 study [4], these early trials are largely con-
founded by the perceived suboptimal efficacy of the
control treatments when compared with optimal anthracy-
cline-containing regimens.
Although many of the taxane trials will not report for some
time, reports from two large European anthracycline trials
are expected at the Annual Meeting of the American
Society for Clinical Oncology this year (Chicago, IL, 31
May 2003). Encouragingly, the French Adjuvant Study
Group 05 (previously reported by Citron and coworkers
[5]) presented the 10-year update on a trial comparing
two doses of FEC (5-fluorouracil, epirubicin, cyclophos-
phamide) in the treatment of poor prognosis patients. This
demonstrated ongoing DFS and OS advantage of patients
treated at the higher dose.
Dose density, as opposed to total dose, may be an impor-
tant variable in the context of adjuvant chemotherapy. Larry
Norton (Memorial-Sloan Kettering Cancer Centre, New
York, USA) outlined the rationale for this. Piccart reviewed
the recent findings of the CALGB 9741 trial [6], which
demonstrated a marked benefit from increased dose
density without altering the total amount and type of drugs
used. This is clearly an area to be addressed in future trials.
Issues in radiotherapy
Intra-operative electron therapy is a new approach cur-
rently undergoing trial evaluation in Milan and this was
described by Roberto Orecchia (European Institute of
Oncology, Milan, Italy). Oscar Streeter (Norris Cancer
Centre, Los Angeles, CA, USA) described a North Ameri-
can brachytherapy approach in which sealed sources are
introduced into a balloon placed intraoperatively in the
tumour cavity following conservative surgery. Such an
approach of partial breast irradiation is based on the
assumption that the great majority of local relapses occur
in the affected quadrant. However, Harry Bartelink
(Netherlands Cancer Institute, Amsterdam, The Nether-
lands) cautioned against its application outwith clinical
trials, citing Danish data that challenged this assumption.
Bartelinck also challenged the practice of restricting post-
mastectomy radiotherapy to patients with heavy nodal
involvement. The Danish data suggested that these
patients gain relatively less from radiotherapy than do
patients with lighter or no nodal involvement.200
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Pathology
With the plethora of new prognostic and predictive tests
currently under evaluation, it is essential that assays and
techniques are reliable and standardized between centres.
Barry Gusterson (University of Glasgow, Glasgow, UK)
reminded us that there is still no consensus on the defini-
tion (or importance) of lymph node micrometastasis, and
Giuseppe Viale (European Institute of Oncology, Milan,
Italy) highlighted the ongoing issues of quality assurance.
These issues have important consequences for the plan-
ning and interpretation of multicentre trials, and the intro-
duction of new technologies such as microarrays will
present new challenges in this regard.
Viale discussed special histological subtypes with prog-
nostic importance, in particular ductal carcinoma with
extensive necrosis/fibrosis, which carries a particularly poor
prognosis even in the absence of lymph node metastasis.
Surgical issues
It is clear that sentinel lymph node biopsy is becoming the
standard of care in many large centres. The emphasis is on
this being a purely diagnostic procedure, and William Wood
(Emory University Hospital, Atlanta, GA, USA) described his
own practice in which patients undergo sentinel lymph node
biopsy before definitive surgery in order that all the relevant
prognostic and staging information can be obtained before
planning therapy. This allows careful multidisciplinary evalu-
ation and optimizes the use of preoperative systemic
therapy. Although in his centre this practice enabled better
cosmetic results and did not have a deleterious effect on
outcome, no data have demonstrated superior survival after
preoperative chemotherapy. Marco Colleoni (European
Institute of Oncology, Milan, Italy) pointed out that the
increased use of preoperative chemotherapy is of consider-
able interest, because this would enable the rapid assess-
ment of predictive factors at an individual patient level rather
than at a trial population level.
Wood and Viviana Galimberti (European Institute of
Oncology, Milan, Italy) both discussed the value of biopsy
of the internal mammary node as part of the sentinel node
procedure because this ‘upstages’ cancer in around 10%
of cases.
New drugs
José Baselga (Hospital Universitario Vall d’Hebron,
Barcelona, Spain) discussed existing and new
approaches to growth factor signalling pathways. In par-
ticular he discussed 2C4, a monoclonal antibody to Her2
that has the potential to block promitotic signalling path-
ways even in those cancers that do not over-express this
receptor. V Craig Jordan (Northwestern University Medical
School, Chicago, IL, USA) described further potential for
new agents in the oestrogen pathway, but also outlined an
interesting rationale for cyclic use of agonists, antagonists
and oestrogen deprivation in the management of breast
cancer.
Chemoprevention
Many speakers referred to several large trials of hormone
manipulation as a primary preventive strategy in high-risk
groups (reviewed by Powles [7]). However, the general
view was one of caution. Andrea Decensi (European Insti-
tute of Oncology, Milan, Italy) highlighted the fact that
none of the studies have (yet) demonstrated any survival
advantage using this approach, and Jack Cuzick (Cancer
Research UK, London, UK) pointed out the relatively high
number of toxic complications of therapy experienced.
Pregnancy and prognosis
Henning Mouridsen (Rigshospitalet, Copenhagen,
Denmark) presented data from the Danish Cancer Reg-
istry suggesting that pregnancy has little or no effect on
the prognosis of breast cancer presenting before, during
or after pregnancy (with the exception that breast cancer
presenting within 2 years of pregnancy carries a poor
prognosis). There is, thus, little evidence to discourage
women who have had breast cancer from having children.
Ductal carcinoma in situ
Staging, surgery and the role of radiotherapy for ductal
carcinoma in situ were discussed. The general consensus
regarding treatment was that postoperative radiotherapy
significantly reduced the incidence of local recurrence, but
that there was no evidence that this treatment had any sig-
nificant impact on OS. The question of how to select
those patients who would benefit from postoperative
radiotherapy remains unanswered. Melvin Silverstein
(Norris Cancer Centre, Los Angeles, CA, USA) and
coworkers initially reported the Van Nuys Prognostic
Index, a quantitative algorithm that used tumour size,
margin width, grade and comedo-type necrosis to predict
the likelihood of local recurrence following breast conser-
vation treatment in patients with ductal carcinoma in situ
[8]. At this meeting he presented an updated version of
the index, which also included the patient’s age as an
independent factor, as a guide to assessing the patient’s
need for postoperative radiotherapy.
Conclusion
The consensus statement from the 8th St Gallen Breast
Cancer Conference will be an important guide to the man-
agement of early breast cancer over the next 2 years.
Although change is, of necessity, a slow process, this
meeting offered stimulating debates, some of which will
impact upon this year’s statement and some of which will
affect statements in years to come.
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